Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) experienced a decline of 1.24% on February 5, with a trading volume of 48.6647 million yuan [1] - The fund's shares increased by 2 million, bringing the total shares to 2.023 billion, with a total increase of 161 million shares over the last 20 trading days [1] - The latest net asset value is calculated at 1.633 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Stock Connect Innovative Drug ETF is the National Index for Hong Kong Stock Connect Innovative Drugs (adjusted for valuation exchange rates) [1] - The fund is managed by Southern Fund Management Co., Ltd., with fund managers Zhang Qisi and Ye Zhenan [1] - Since its establishment on September 12, 2025, the fund has reported a return of -19.30%, with a return of -2.93% over the past month [1]

Group 1 - The Hong Kong Innovative Drug 50 ETF (513780) increased by 0.06% on December 10, with a trading volume of 238 million yuan [1] - The fund's shares increased by 23.5 million, bringing the total shares to 1.802 billion, although there was a decrease of 54 million shares over the last 20 trading days [1] - The latest net asset value of the fund is 2.995 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug 50 ETF is the CSI Hong Kong Stock Connect Innovative Drug Index return rate, adjusted for valuation exchange rates [1] - The fund is managed by Invesco Great Wall Fund Management Co., with Jin Huang as the fund manager [1] - Since its establishment on October 16, 2024, the fund has achieved a return of 66.26%, while the return over the past month is -2.52% [1]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF managed by Southern Fund experienced a decline of 0.69% on November 11, with a trading volume of 819.30 million yuan, indicating a challenging market environment for innovative drug investments [1] Group 1: Fund Performance - The fund's total shares increased by 75 million, bringing the latest total to 1.568 billion shares, with an increase of 818 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated at 1.355 billion yuan [1] - Since its establishment on September 12, 2025, the fund has reported a return of -13.60%, while the return over the past month is -8.36% [1] Group 2: Management and Benchmark - The fund is managed by Southern Fund Management Co., Ltd., with fund managers Zhang Qisi and Ye Zhenan [1] - The performance benchmark for the fund is the Guozhen Hong Kong Stock Connect Innovative Drug Index, adjusted for valuation exchange rates [1]

Core Viewpoint - The Hong Kong Innovative Drug ETF managed by Penghua has shown a slight increase in value, but its overall performance since inception has been negative, indicating potential challenges in the sector [1]. Group 1: Fund Performance - The Hong Kong Innovative Drug ETF (159286) increased by 0.11% on November 6, with a trading volume of 71.5588 million yuan [1]. - The fund's total shares increased by 1 million, bringing the total to 694 million shares, with a notable increase of 14.5 million shares over the last 20 trading days [1]. - The latest net asset value of the fund is 622 million yuan [1]. Group 2: Benchmark and Management - The performance benchmark for the fund is the National Index of Hong Kong Innovative Drugs, adjusted for exchange rates [1]. - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang [1]. - Since its establishment on August 20, 2025, the fund has recorded a return of -10.40%, and a return of -11.44% over the past month [1].

Group 1 - The Hong Kong Innovative Drug ETF (159567) experienced a decline of 1.32% on August 1, with a trading volume of 3.137 billion yuan [1] - The fund's shares decreased by 20 million, bringing the total shares to 2.447 billion, with an increase of 450 million shares over the past 20 trading days [1] - The latest net asset value of the fund is 4.532 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF is the National Index of Hong Kong Innovative Drugs, adjusted for valuation exchange rates [1] - The fund is managed by Yinhua Fund Management Co., Ltd., with Ma Jun as the fund manager [1] - Since its inception on January 3, 2024, the fund has achieved a return of 85.16%, with a return of 22.72% over the past month [1]

Group 1 - The Hong Kong Innovative Drug 50 ETF (513780) increased by 4.15% on July 29, with a trading volume of 985 million yuan [1] - The fund's shares rose by 80.5 million, bringing the total shares to 844 million, with an increase of 87.5 million shares over the last 20 trading days [1] - The latest net asset value of the fund is calculated at 1.606 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug 50 ETF is the CSI Hong Kong Stock Connect Innovative Drug Index return rate, adjusted for valuation exchange rates [1] - The fund is managed by Invesco Great Wall Fund Management Co., with fund managers Jin Huang and Zhang Xiaonan [1] - Since its establishment on October 16, 2024, the fund has achieved a return of 90.41%, with a one-month return of 32.21% [1]

Group 1 - The pharmaceutical sector in China is experiencing a resurgence after over three years of stagnation, driven by overseas business and innovative drug companies turning profitable [1] - In 2024, the total transaction value of Chinese innovative drugs going abroad is projected to reach $50.8 billion, marking a year-on-year increase of over 30% [1] - The National Medical Products Administration reported that 48 new Class 1 innovative drugs were approved for market in 2024, a 20% increase year-on-year, achieving a five-year high [1] Group 2 - Major companies are reporting strong financial results, with BeiGene's Q1 revenue reaching 8.048 billion yuan, a 50.2% year-on-year increase, marking its first quarterly profit [1] - WuXi AppTec, a leading CXO company, reported Q1 revenue of 9.65 billion yuan, a 21.0% increase year-on-year, with net profit attributable to shareholders at 3.67 billion yuan, up 89.1% [1] Group 3 - The innovative drug-related indices have seen significant increases, with leading indices reflecting strong performance from innovative drug companies [1] - The top ten constituent stocks of the National and China Securities innovative drug indices show a high similarity, indicating a strong leader effect [2] Group 4 - The leading constituent stock, Innovent Biologics, reported Q1 product sales exceeding 2.4 billion yuan, a year-on-year increase of over 40%, achieving a record high for a single quarter [3] - BeiGene's stock has increased by 45.51% this year, while WuXi Biologics has seen a 51.77% increase [4] Group 5 - There are currently three ETFs tracking the National innovative drug index, with the largest being the Huatai-PineBridge ETF, which has a scale of 4.474 billion yuan [4] - The two ETFs tracking the China Securities innovative drug index are smaller in scale compared to those tracking the National index [5] Group 6 - The Hang Seng innovative drug index and the Hang Seng Hong Kong Stock Connect innovative drug index have similar constituent stocks, with significant overlap in their top ten holdings [6] - The Hang Seng Hong Kong Stock Connect healthcare index has a more concentrated composition, leading to more pronounced gains during market upswings [9] Group 7 - The average growth rate for innovative drug revenues is projected at 36.8% for 2024, with many companies reducing losses significantly and some achieving profitability [12] - The current valuation of innovative drug companies is considered reasonable after three years of adjustments, with the industry entering a growth cycle [12]